mRNA-4157 Plus Pembrolizumab Bolsters RFS in Resected Melano

The addition of mRNA-4157 to pembrolizumab led to clinically significant improvements in relapse-free survival and distant metastasis–free survival vs pembrolizumab alone in patients with high-risk resected melanoma.

Related Keywords

, Jeffrey Weber , Langone Health , Perlmutter Cancer Center , Resected Melanoma , Mrna 4157 , Pembrolizumab , Esmo Congress ,